Protalix BioTherapeutics, Inc.

PLX
$1.97 (- $0.01 - 0.51%)
Last updated: 2026-06-11 00:40 UTC
PLX Metrics
Exchange
🇺🇸 NYSE XASE
NYSE Mkt LLCUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINNL0015001W49
Market Price1.97
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E Ratio22.12
EPS0.08
Market Cap$142.3M
Book Value0.66
Price to Book2.686
Beta-0.25
52w High3.1
52w Low1.32
Next Earnings DateN/A

Protalix BioTherapeutics, Inc. trades under ticker PLX on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN NL0015001W49.

About the Company
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Price History